GOCOVRI 137 mg/1 (Amantadine CAPSULE, COATED PELLETS) 137 mg/1

GOCOVRI 137 mg/1 is a coated pellet capsule containing amantadine, used for managing certain movement disorders. This medication is designed for oral administration and is manufactured by Supernus Pharmaceuticals in the USA.

Strength

137 mg/1

Pack Size

21 CAPSULE, COATED PELLETS in 1 BOTTLE (17772-170-21)

Manufacturer / TM Owner

Supernus Pharmaceuticals

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

GOCOVRI 137 mg/1 is primarily used to help manage symptoms associated with movement disorders. Amantadine, the active ingredient, is often prescribed to address specific motor function issues. Patients may wonder, 'What is GOCOVRI used for?' This medication is typically utilized as part of a broader treatment plan for conditions affecting movement and coordination.

Side Effects

Common effects of GOCOVRI 137 mg/1 may include changes in motor function and potential side effects such as dizziness or nausea. Individual responses can vary, and it's important to monitor how the body reacts to the medication. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

When handling GOCOVRI 137 mg/1, it's important to follow the prescribed dosage and administration instructions. Store the medication in a cool, dry place away from direct sunlight. Avoid sudden changes in dosage without consulting a healthcare professional.

Avoid Interactions

GOCOVRI 137 mg/1 may interact with certain medications, including those that affect the central nervous system. Alcohol and other depressants should be avoided unless approved by a healthcare provider. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

GOCOVRI 137 mg/1 is used to manage symptoms associated with movement disorders, often as part of a broader treatment plan.

GOCOVRI 137 mg/1 is taken orally, typically following the dosage instructions provided by your healthcare provider.

Common side effects may include dizziness, nausea, and changes in motor function. Individual responses can vary.

It is generally advised to avoid alcohol while taking GOCOVRI 137 mg/1 unless approved by your healthcare provider.

Store GOCOVRI 137 mg/1 in a cool, dry place away from direct sunlight and out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.